Openbookopenbook
Equity
cbdMD Inc(YCBD)
USD --+0.00%
Reward37Moderate
Risk70High
📊75%Data
Thin -8% profit margin · Revenue down 11% YoY
YCBD
+0.0 · +0.00%
USD · NYSE MKT
cbdMD Inc | Healthcare
Earnings Deterioration
Market Cap:6.58M
ℹ️
Reward Rating
37
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
70
High
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on YCBD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $2.00.

What is cbdMD Inc?

produces and distributes various cannabidiol (CBD) products in the United States and internationally.

YCBD · Verdict

Limited reward · elevated risk

YCBD has limited near-term tailwinds — volatility and cash flow weigh on the model output.

Based on 88% data coverage

YCBD · Verdict

What’s working & what to watch

Watchouts 5

  • Volatility5/100

    Weak vs peers

  • Cash flow25/100

    -9% free-cash-flow margin

  • Profitability28/100

    -11% net margin · -33% ROE

  • Valuation34/100

    P/E 714.3×

  • Growth35/100

    Rev -18.5% CAGR · earnings -69.2%

Model-based scoring. For information only — not financial advice.

What is cbdMD Inc?

produces and distributes various cannabidiol (CBD) products in the United States and internationally. The company owns and operates various consumer hemp-based CBD brands. The company is listed on the NYSE MKT in USA, operating in the Healthcare sector, with a market capitalisation of 6.58M, and a P/E ratio of 1.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Moderate volatility with meaningful macro and earnings sensitivity.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (37)

The scoring profile indicates weak reward characteristics across most factors, including momentum and size. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap6.58M
P/E Ratio1.4471
Dividend YieldN/A
52 Week High3.36
52 Week Low0.47
Last AnnualSeptember
IPO Date4/29/2019
IncorporatedUSA
Shares Outstanding9M
No. of Employees42
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNYSE MKT
Beta2.214
CurrencyUSD
Websitewww.cbdmd.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.